Focused on cancers with large patient populations and significant unmet need.
About OncoCyte Stock
OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.The company believes that better and earlier detection of cancer through liquid biopsies will: Improve patient outcomes Increase the life expectancy of cancer patients Significantly reduce health care costs Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.
President & CEO
Yankee Analysts - Jun, 27 2018
The Herald - Jun, 27 2018
Park City Caller - Jun, 26 2018
The Ledger Gazette - Jun, 24 2018
The Lincolnian Online - Jun, 19 2018
GenomeWeb - May, 15 2018